| Literature DB >> 2504171 |
G W Cannon1, S H Pincus, R D Emkey, A Denes, S A Cohen, F Wolfe, P A Saway, A M Jaffer, A L Weaver, L Cogen.
Abstract
One hundred five patients were enrolled in a 12-week, randomized, prospective, double-blind, placebo-controlled trial of recombinant human gamma-interferon (rHu gamma-IFN) for the treatment of rheumatoid arthritis. Fifty-four patients received rHu gamma-IFN and 51 received placebo. Forty-two patients in each group completed the 12-week trial. Some clinical improvement occurred in both groups of patients. Although the improvement with rHu gamma-IFN was greater than that with placebo, the differences were generally not statistically significant.Entities:
Mesh：
Substances：
Year: 1989 PMID： 2504171 DOI： 10.1002/anr.1780320805
Source DB: PubMed Journal: Arthritis Rheum ISSN： 0004-3591